Abbott's FreeStyle Libre 3 Plus Now Covered Across Canada

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...
The American Journal of Managed Care

FDA Approves Freestyle Libre CGM With 14-Day Sensor

The system was the first to allow people with diabetes to monitor blood glucose without fingersticks. Abbott’s 14-day Freestyle Libre continuous glucose monitor (CGM) has been approved by the FDA, ...
Seeking Alpha

t:slim X2™ Insulin Pump Now Available with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States

Tandem Diabetes Care (TNDM) begins global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor, expanding choice and personalization for people living with ...
Cantech Letter

Health Canada approves expanded compatibility for mylife Loop with iOS and Abbott’s FreeStyle Libre 3 Plus Sensor

Loop powered by mylife CamAPS FX becomes the first automated insulin delivery system in Canada compatible with two glucose monitoring systems for people living with type 1 diabetes ...
Monthly Prescribing Reference

FreeStyle Libre 2 Cleared for Use in Adults and Pediatric Patients With Diabetes

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...